Clinical features and prognosis of hepatocellular carcinoma with respect to pre-S deletion and basal core promoter mutations of hepatitis B virus Genotype C2.

[Guest guest]

J Med Virol. 2011 Dec;83(12):2088-95. doi: 10.1002/jmv.22238.

Clinical features and prognosis of hepatocellular carcinoma with respect to

pre-S deletion and basal core promoter mutations of hepatitis B virus Genotype

C2.

Ryu HJ, Kim do Y, Park JY, Chang HY, Lee MH, Han KH, Chon CY, Ahn SH.

Source

Department of Internal Medicine, Yonsei University College of Medicine, Seoul,

South Korea; Liver Cirrhosis Clinical Research Center, Seoul, South Korea.

Abstract

Few studies have reported on the clinical characteristics of hepatocellular

carcinoma (HCC) at the time of diagnosis with regard to pre-S and basal core

promoter (BCP) mutations. In this study, the clinical features and prognosis of

126 Korean HCC patients were examined with respect to pre-S deletion and BCP

mutations of hepatitis B virus. The proportion of HCC patients according to

tumor-node-metastasis stage are as follows: 8.7% in stage I, 31% in stage II,

30.2% in stage III, 21.4% in stage IV-A, and 8.7% in stage IV-B. Overall, 40.5%

of HCC patients were treated by surgery or ablation, 59.5% by other methods.

Patients were divided according to pre-S deletion and BCP mutations (103 without

pre-S deletion, 23 with pre-S deletion; 44 without BCP mutation, 82 with BCP

mutation). The tumor characteristics and prognosis were evaluated between the

groups, including size, number, type, vessel invasion, portal vein thrombosis,

and metastasis. No significant difference in tumor characteristics between the

HCC patients with pre-S deletion was observed, compared with the HCC patients

without pre-S deletion. In contrast, the survival rate was lower in those with

pre-S deletion than in those without it (P = 0.024). No difference in tumor

characteristics was found in non-BCP and BCP mutation patients. Unlike the pre-S

deletion group, no difference was observed in survival rate between the non-BCP

and BCP patients. In conclusion, pre-S deletion and BCP mutations did not affect

the initial tumor features. However, pre-S deletion was an independent risk

factor affecting HCC survival. J. Med. Virol. 83:2088-2095, 2011. © 2011 Wiley

Periodicals, Inc.

Copyright © 2011 Wiley Periodicals, Inc.

PMID: 22012715 [PubMed - in process]

[Guest guest]

J Med Virol. 2011 Dec;83(12):2088-95. doi: 10.1002/jmv.22238.

Clinical features and prognosis of hepatocellular carcinoma with respect to

pre-S deletion and basal core promoter mutations of hepatitis B virus Genotype

C2.

Ryu HJ, Kim do Y, Park JY, Chang HY, Lee MH, Han KH, Chon CY, Ahn SH.

Source

Department of Internal Medicine, Yonsei University College of Medicine, Seoul,

South Korea; Liver Cirrhosis Clinical Research Center, Seoul, South Korea.

Abstract

Few studies have reported on the clinical characteristics of hepatocellular

carcinoma (HCC) at the time of diagnosis with regard to pre-S and basal core

promoter (BCP) mutations. In this study, the clinical features and prognosis of

126 Korean HCC patients were examined with respect to pre-S deletion and BCP

mutations of hepatitis B virus. The proportion of HCC patients according to

tumor-node-metastasis stage are as follows: 8.7% in stage I, 31% in stage II,

30.2% in stage III, 21.4% in stage IV-A, and 8.7% in stage IV-B. Overall, 40.5%

of HCC patients were treated by surgery or ablation, 59.5% by other methods.

Patients were divided according to pre-S deletion and BCP mutations (103 without

pre-S deletion, 23 with pre-S deletion; 44 without BCP mutation, 82 with BCP

mutation). The tumor characteristics and prognosis were evaluated between the

groups, including size, number, type, vessel invasion, portal vein thrombosis,

and metastasis. No significant difference in tumor characteristics between the

HCC patients with pre-S deletion was observed, compared with the HCC patients

without pre-S deletion. In contrast, the survival rate was lower in those with

pre-S deletion than in those without it (P = 0.024). No difference in tumor

characteristics was found in non-BCP and BCP mutation patients. Unlike the pre-S

deletion group, no difference was observed in survival rate between the non-BCP

and BCP patients. In conclusion, pre-S deletion and BCP mutations did not affect

the initial tumor features. However, pre-S deletion was an independent risk

factor affecting HCC survival. J. Med. Virol. 83:2088-2095, 2011. © 2011 Wiley

Periodicals, Inc.

Copyright © 2011 Wiley Periodicals, Inc.

PMID: 22012715 [PubMed - in process]